Telmisartan for stable prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests the blood pressure medication telmisartan in men with prostate cancer who are already on a stable treatment and not needing an immediate change. The goal is to see if adding telmisartan can help control the cancer without extra side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You are on a steady prostate cancer treatment (like cabazitaxel, docetaxel, olaparib, rucaparib, or talazoparib plus enzalutamide) and not needing to switch to a new therapy immediately.
- Your PSA level is either stable or rising slowly (without need for a new treatment right away).
- Your blood pressure is above 110 mmHg when standing, and you can check it at home daily.
- You have not taken an ACE inhibitor (like lisinopril) in the last 6 weeks, and you are not on certain other medicines (like lithium, digoxin without monitoring, or ramapril).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether daily aspirin and atorvastatin can slow advanced prostate cancer that has continued to grow despite hormone therapy. It may help by reducing cancer growth and inflammation, but you would need to meet several specific safety and medication rules.
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
This trial tests a treatment called bipolar androgen therapy for men with prostate cancer that has not spread to other parts of the body and is still growing despite taking darolutamide. The goal is to see if this therapy can help control the cancer.
This trial tests a new combination of drugs given before surgery for locally advanced prostate cancer. The goal is to see if giving these drugs first helps shrink the tumor and improves outcomes after surgery.
This study tests whether adding a diabetes drug called dapagliflozin to standard hormone therapy can help control advanced prostate cancer better than hormone therapy alone. It may slow cancer growth and improve outcomes.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.